NICEATM/ICCVAM INVOLVEMENT IN
The 6th World Congress on Alternatives & Animal Use in the Life Sciences
August 21-25, 2007
Tokyo, Japan

Twelve scientists from or associated with NICEATM and ICCVAM will be attending WC6. Their participation includes 12 oral presentations, 11 poster presentations, 7 session chairs, and 2 members of the conference organizing committee.

NICEATM/ICCVAM ATTENDEES:

NICEATM Staff: William Stokes, Raymond Tice (Dr. Stokes and Dr. Tice also served on the WC6 Organizing Committee)

ILS, Inc. Staff (Contractor Supporting NICEATM): David Allen, Douglas Winters, Judy Strickland, Frank Deal

ICCVAM Members: Margaret Snyder (NIH), Richard McFarland (FDA), Marilyn Wind (CPSC), Jodie Kulpa-Eddy (USDA), Moiz Mumtaz (ATSDR), Amy Rispin (EPA), William Stokes (NIEHS), Raymond Tice (NIEHS)

SCHEDULE OF NICEATM/ICCVAM EVENTS

Wednesday, August 22

Session 9-2(1): Globalization: Validation and International Cooperation
10:15-12:15, Room 1-A

William Stokes: ICCVAM and NICEATM initiatives

First Poster Session
13:30-15:30, Room 1-B

William Stokes: Topical anesthetic pre-treatment in the Draize eye test: Impact on hazard classification (P1-1024)

Raymond Tice: The redesigned NICEATM-ICCVAM website: Improving communication with stakeholders (P1-1066)

William Stokes: Reducing animal use for acute oral toxicity testing: ICCVAM recommendations for the use of *in vitro* cytotoxicity test methods (P1-1068)

Session 4-4: Methodology for the Validation Process of Alternative Assays
16:15-18:45, Room 3-G

Amy Rispin: Reference chemicals: issues and challenges

Session 5-12: Comet Assay
Chairs: **Raymond Tice** and Brian Barlinson

16:15-18:45, Room 3-E

Raymond Tice: The comet assay: an overview

Session 10-3: Linking Risk Assessment and Risk Management
16:15-18:45, Room 3-F

Marilyn Wind: Risk assessment approach and regulation

Thursday, August 23

Session 4-3: Regulatory Requirements for the Consideration of Alternatives
10:15-12:15, Room 1-A

Jodie Kulpa-Eddy: U.S. perspective on the "consideration of alternatives" regulatory requirement

Session 5-1: Alternatives for Acute Systemic Toxicity
Chairs: **Raymond Tice** and Silvia Casati
13:00-15:00, Room 3-C

Raymond Tice: Alternatives for acute oral systemic toxicity testing: NICEATM/ICCVAM current and planned activities

Judy Strickland: The NICEATM/ECVAM validation study of in vitro cytotoxicity test methods for estimating rat oral acute toxicity

Session 5-2: Research, development and evaluation of alternatives for ocular toxicity
Chairs: **William Stokes** and Odile deSilva
13:00-15:00, Room 3-F

William Stokes: Alternatives for ocular toxicity testing: ICCVAM and NICEATM recent and planned initiatives

Session 7-2: 3R's Achievement in Other Biologicals Quality Control
Chairs: **Richard McFarland** and Toru Kawanishi
13:00-15:00, Room 3-J

Richard McFarland: 3Rs in gene therapies and cellular therapies in USA

Session 10-2: Assessment of Animal Health Risks and Animal Welfare Risks
13:00-15:00, Room 1-A

Moiz Mumtaz: The use of alternative methods in public health practice must be deliberative and judicious

Friday, August 24

Session 2-4: Public Participation in Decision-Making on Animal Use in Different Cultural Contexts
Chairs: **Margaret Snyder** and Baroness Perry of Southwark
10:15-12:15, Room 3-E

Second Poster Session

15:30-17:30, Room 1-B

William Stokes: *In vitro* cytotoxicity test methods for estimating rat acute oral toxicity: Prediction of GHS acute oral toxicity categories (P2-2002)

Amy Rispin: *In vitro* cytotoxicity test methods for estimating starting doses for rat acute oral toxicity tests: Impact on animal savings (P2-2003)

Karen Hamernik: ICCVAM recommendations for the use of *in vitro* test methods for the identification and classification of ocular corrosives and severe irritants (P2-2008)

Raymond Tice: Relationship between adverse ocular effects and their reversibility (P2-2017)

David Hattan: ICCVAM revised recommended substances for the validation of *in vitro* estrogen receptor and androgen receptor binding and transcriptional activation test methods (P2-2102)

Raymond Tice: Standardization of protocols for the validation of an *in vitro* estrogen receptor transcriptional activation assay (P2-2103)

William Stokes: NICEATM/ECVAM/JaCVAM multi-phased international validation study of an *in vitro* estrogen receptor transcriptional activation assay to detect agonist and antagonist activity (P2-2104)

Jodie Kulpa-Eddy: Alternatives to the mouse LD_{50} assay for botulinum toxin testing: An ICCVAM/NICEATM/ECVAM sponsored workshop (P2-2122)

Richard McFarland: NICEATM and ICCVAM evaluation of five *in vitro* test methods for assessing potential pyrogenicity of pharmaceuticals and other products (P2-2124)

Saturday, August 25

Session 2-2 (2): Impacts of Policy Implementation on Trends in Animal Use and Science
10:15-12:15, Room 3-G

Jodie Kulpa-Eddy: A review of trends in animal use in the United States

Session 5-10: Validation
Chairs: **Hajime Kojima** and **William Stokes**
10:15-12:15, Room 3-C

Marilyn Wind: The ICCVAM process for validation and evaluation of new and alternative methods